Pemphigus: current and future therapeutic strategies

D Didona, R Maglie, R Eming, M Hertl - Frontiers in immunology, 2019 - frontiersin.org
Pemphigus encompasses a heterogeneous group of autoimmune blistering diseases, which
affect both mucous membranes and the skin. The disease usually runs a chronic-relapsing …

Bullous pemphigoid

IS Bağcı, ON Horváth, T Ruzicka, M Sárdy - Autoimmunity reviews, 2017 - Elsevier
Bullous pemphigoid (BP) is the most common autoimmune bullous disorder which is
characterized by autoantibodies against hemidesmosomal proteins of the skin and mucous …

Pemphigus. S2 Guideline for diagnosis and treatment–guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology …

M Hertl, H Jedlickova, S Karpati… - Journal of the …, 2015 - Wiley Online Library
Background Pemphigus encompasses a group of life‐threatening autoimmune bullous
diseases characterized by blisters and erosions of the mucous membranes and skin. Before …

[PDF][PDF] Федеральные клинические рекомендации по оказания медицинской помощи детям с Желчекаменной болезнью

АА Баранов, ЛС Намазова-Баранова - МЗ РФ, Союз педиатров …, 2015 - astgmu.ru
Данные клинические рекомендации подготовлены совместно с Всероссийской
ассоциацией для больных муковисцидозом, рассмотрены и утверждены на заседании …

Paraneoplastic pemphigus: insight into the autoimmune pathogenesis, clinical features and therapy

G Paolino, D Didona, G Magliulo, G Iannella… - International Journal of …, 2017 - mdpi.com
Paraneoplastic pemphigus is a rare autoimmune skin disease that is always associated with
a neoplasm. Usually, oral, skin, and mucosal lesions are the earliest manifestations shown …

Interventions for bullous pemphigoid

G Kirtschig, P Middleton, C Bennett… - Cochrane Database …, 2010 - cochranelibrary.com
Interventions for bullous pemphigoid - Kirtschig, G - 2010 | Cochrane Library Skip to Content
Cookies Our site uses cookies to improve your experience. You can find out more about our …

Different response to rituximab in tumor necrosis factor blocker–naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor …

IH Song, F Heldmann, M Rudwaleit… - Arthritis & …, 2010 - Wiley Online Library
Objective Histologic studies have shown B cell clusters in the subchondral bone marrow of
the spine of patients with ankylosing spondylitis (AS). An immunotherapy targeting B cells in …

Autoimmune bullous skin diseases. Part 2: diagnosis and therapy

A Kneisel, M Hertl - JDDG: Journal der Deutschen …, 2011 - Wiley Online Library
Autoimmune bullous skin diseases represent a heterogenous group of disorders of skin and
mucosa which are commonly associated with IgG or IgA autoantibodies against distinct …

Serological diagnosis of autoimmune bullous skin diseases

S Saschenbrecker, I Karl, L Komorowski… - Frontiers in …, 2019 - frontiersin.org
Autoimmune bullous dermatoses (AIBD) encompass a variety of organ-specific autoimmune
diseases that manifest with cutaneous and/or mucosal blisters and erosions. They are …

Post-rituximab immunoglobulin M (IgM) hypogammaglobulinemia

K Kridin, AR Ahmed - Autoimmunity reviews, 2020 - Elsevier
Rituximab is a B cell depleting monoclonal antibody that targets the B cell-specific cell
surface antigen CD20 and is currently used to treat several autoimmune diseases. The …